

ORASURE TECHNOLOGIES INC  
Form 8-K  
November 17, 2003

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

### CURRENT REPORT

#### PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 17, 2003

---

## OraSure Technologies, Inc.

(Exact name of issuer as specified in charter)

<b>DELAWARE</b>	<b>001-16537</b>	<b>36-4370966</b>
(State or Other Jurisdiction of Incorporation or Organization)	(Commission file number)	(I.R.S. Employer Identification Number)

**220 East First Street**  
**Bethlehem, Pennsylvania 18015-1360**  
(Address of principal executive offices)

**(610) 882-1820**

**(Registrant's telephone number, including area code)**

---

**Item 5 Other Events and Regulation FD Disclosure.**

OraSure Technologies, Inc. (the Company) issued a press release on November 17, 2003, announcing that it will be submitting additional data to the U.S. Food and Drug Administration in support of an HIV-2 claim for the Company's OraQuick® Rapid HIV-1 Antibody Test. The information contained in the press release is incorporated herein by reference and attached to this Current Report on Form 8-K as Exhibit 99.

**Item 7. Financial Statements and Exhibits**

**(c) Exhibits**

<u>Exhibit Number</u>	<u>Description</u>
99	Press Release dated November 17, 2003, announcing that OraSure Technologies, Inc. will be submitting additional data to the U.S. Food and Drug Administration in support of an HIV-2 claim for its OraQuick® Rapid HIV-1 Antibody Test.



**Index to Exhibits**

<b><u>Exhibit Number</u></b>	<b><u>Description</u></b>
99	Press Release dated November 17, 2003, announcing that OraSure Technologies, Inc. will be submitting additional data to the U.S. Food and Drug Administration in support of an HIV-2 claim for its OraQuick® Rapid HIV-1 Antibody Test.